Subcutaneous administration of botulinum toxin A reduces formalin-induced pain
Allergan (Ireland) · DuPont (United States)
Indexed incrossrefpubmed
Abstract
Botulinum toxin type A (BoNT-A) produced by the bacterium Clostridium botulinum is a potent inhibitor of acetylcholine release in the neuromuscular junction and has been used to treat many disorders related to excessive muscle contraction. However, BoNT-A has recently been used in pain therapy to treat myofascial pain, low back pain and various types of headaches, including migraine. The purpose of this study is to investigate the antinociceptive effect of BoNT-A and its underlying mechanism in the rat formalin inflammatory pain model. BoNT-A (3.5, 7, 15 and 30 U/kg) or vehicle was administered to the plantar surface of the right hindpaw of male Sprague-Dawley rats. BoNT-A dose-dependently (P
Citation impact
674
total citations
- FWCI
- 18.72
- Percentile
- 100%
- References
- 63
Citations per year
Authors
4Topics & keywords
Topics
Keywords
- Nociception
- Medicine
- Botulinum toxin
- Anesthesia
- Pharmacology
- Clostridium botulinum
- Internal medicine
- Toxin
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.